US 12,365,644 B2Granted

Co-crystal of ketoprofen, lysine and gabapentin, pharmaceutical compositions and their medical use

AssigneeDompé Farmaceutici S.P.A.

InventorsAndrea Aramini, Marcello Allegretti, Gianluca Bianchini, Samuele Lillini, Mara Tomassetti

Life of this patent

Estimating the term…

Abstract

The present invention relates to a new co-crystal of Ketoprofen, Lysine and Gabapentin, to pharmaceutical compositions and to their use in the prevention, reduction or treatment of pain and/or inflammation.

Claims18

Dependent claims

A co-crystal of Ketoprofen, Lysine and Gabapentin, wherein the molar ratio of the components is 1:1:2.

Dependencies are inferred from the claim text.

Facts

Application: 17/922,999Filed 4 May 2021
Priority: EP 201726604 May 2020
Published: US 2023/0357121 A19 Nov 2023
Granted: 22 Jul 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07C 59/84
Containing keto groups: containing six membered aromatic rings
C07C 229/26
The carbon skeleton being acyclic and saturated: having more than one amino group bound to the carbon skeleton, e.g. lysine
C07C 229/28
Having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton: the carbon skeleton being saturated and containing rings
C07B 2200/13
Indexing scheme relating to specific properties of organic compounds: crystalline forms, e.g. polymorphs

Family

US 2023/0357121 A1Pre-grant publication · published 9 Nov 2023
US 12,365,644 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results